The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancers

BACKGROUND: KRAS is mutated in ∼90% of pancreatic ductal adenocarcinomas, ∼35% of colorectal cancers and ∼20% of non-small-cell lung cancers. There has been recent progress in targeting (G12C)KRAS specifically, but therapeutic options for other mutant forms of KRAS are limited, largely because the c...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Ann Oncol
Huvudupphovsmän: Saturno, G., Lopes, F., Niculescu-Duvaz, I., Niculescu-Duvaz, D., Zambon, A., Davies, L., Johnson, L., Preece, N., Lee, R., Viros, A., Holovanchuk, D., Pedersen, M., McLeary, R., Lorigan, P., Dhomen, N., Fisher, C., Banerji, U., Dean, E., Krebs, M.G., Gore, M., Larkin, J., Marais, R., Springer, C.
Materialtyp: Artigo
Språk:Inglês
Publicerad: Oxford University Press 2021
Ämnen:
Original Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC7839839/
https://ncbi.nlm.nih.gov/pubmed/33130216
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.annonc.2020.10.483
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk